NEW YORK (TheStreet) -- NewLink Genetics (NLNK) shares are up 9.9% to $25.75 on Thursday after the drug developer announced that it is prepared to begin the initial round of human testing for an Ebola vaccine.
The company has not set up a timetable to begin testing, though they are receiving outside assistance to help accelerate the trials.
"We're getting a lot of assistance from a number of sources to accelerate this, so exactly how long it's going to take is a little uncertain because people are greasing the paths as much as they can," said company CFO Gordon Link.
EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.
There is currently no proven treatment for the disease which has caused over 1,000 deaths in an outbreak in Western Africa this summer.
The company said that tests would involve 100 healthy volunteers and that the vaccine has been 100% effective in preventing infections in primates.
TheStreet Ratings team rates NEWLINK GENETICS CORP as a Sell with a ratings score of D+. TheStreet Ratings Team has this to say about their recommendation:
"We rate NEWLINK GENETICS CORP (NLNK) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income."